Continuous Improvement and the Expansion of Quality ... - NCQA
Continuous Improvement and the Expansion of Quality ... - NCQA
Continuous Improvement and the Expansion of Quality ... - NCQA
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
178<br />
MEASURE<br />
N AT I o N A l C o M M I T T E E f o R Q U A l I T y A S S U R A N C E<br />
HEdIs EffECtIvEnEss <strong>of</strong> CarE MEasurEs<br />
MEdICaId HMo statIstICs—2010<br />
90TH<br />
PERCENTIlE<br />
10TH<br />
PERCENTIlE DIffERENCE<br />
Disease Modifying Anti-Rheumatic Drug Therapy in Rheumatoid Arthritis 83.2 53.3 29.8<br />
Use <strong>of</strong> Appropriate Medications for People With Asthma—5–11 years 96.0 87.5 8.5<br />
Use <strong>of</strong> Appropriate Medications for People With Asthma—12–50 years 91.3 79.8 11.4<br />
Use <strong>of</strong> Appropriate Medications for People With Asthma—overall Rate 93.2 83.6 9.6<br />
Use <strong>of</strong> Spirometry Testing in <strong>the</strong> Assessment <strong>and</strong> Diagnosis <strong>of</strong> CoPD 47.2 19.1 28.0<br />
Pharmaco<strong>the</strong>rapy Management <strong>of</strong> CoPD—bronchodilators 89.3 71.1 18.2<br />
Pharmaco<strong>the</strong>rapy Management <strong>of</strong> CoPD—Systemic Corticosteroids 76.8 46.5 30.3<br />
Annual Monitoring for Patients on Persistent Medications—ACE Inhibitors or ARbs 90.6 79.9 10.7<br />
Annual Monitoring for Patients on Persistent Medications—Anticonvulsants 76.6 57.6 19.0<br />
Annual Monitoring for Patients on Persistent Medications—Digoxin 95.5 80.4 15.1<br />
Annual Monitoring for Patients on Persistent Medications—Diuretics 90.7 79.3 11.3<br />
Annual Monitoring for Patients on Persistent Medications—Combined 88.1 78.3 9.9<br />
Antidepressant Medication Management—Acute Phase 59.9 43.0 16.9<br />
Antidepressant Medication Management—Continuation Phase 44.2 25.7 18.5<br />
follow-Up After Hospitalization for Mental Illness—Within 7 Days Post-Discharge 68.3 23.0 45.3<br />
follow-Up After Hospitalization for Mental Illness—Within 30 Days Post-Discharge 82.6 36.0 46.6<br />
Alcohol <strong>and</strong> o<strong>the</strong>r Drug Dependence Treatment—Engagement 25.9 2.0 23.9<br />
Alcohol <strong>and</strong> o<strong>the</strong>r Drug Dependence Treatment—Initiation 60.7 30.0 30.7<br />
Measures targeted toward Children <strong>and</strong> adolescents<br />
Appropriate Testing for Children With Pharyngitis 83.0 45.1 37.9<br />
Appropriate Testing for Children With Upper Respiratory Infection 94.8 79.2 15.6<br />
Childhood Immunization Status—DTaP/DT 88.5 70.8 17.7<br />
Childhood Immunization Status—Hepatitis b 95.9 82.9 13.0<br />
Childhood Immunization Status—Hib 96.1 84.3 11.8<br />
Childhood Immunization Status—IPV 95.9 85.6 10.2<br />
Childhood Immunization Status—MMR 95.4 86.1 9.3<br />
Childhood Immunization Status—Pneumococcal Conjugate (PCV) 88.8 68.8 20.0<br />
Childhood Immunization Status—VzV 95.1 85.4 9.7<br />
Childhood Immunization Status—Combination 2<br />
(DTaP, IPV, MMR, Hib, Hepatitis b <strong>and</strong> VzV)<br />
Childhood Immunization Status—Combination 3<br />
(DTaP, IPV, MMR, Hib, Hepatitis b, VzV <strong>and</strong> PCV)<br />
85.8 62.3 23.6<br />
82.6 56.8 25.8<br />
Childhood Immunization Status—Hepatitis A 48.7 24.3 24.4<br />
Childhood Immunization Status—Rotavirus 72.2 43.6 28.7<br />
Childhood Immunization Status—Influenza 60.3 22.0 38.3